Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial by Staplin, N, Haynes, R, Herrington, W, Judge, P, Emberson, J, Preiss, D, Mayne, K, Sammons, E, Zhu, D, Hill, M, Stevens, W, Wallendszus, K, Landray, M, Baigent, C, The EMPA-KIDNEY Collaborative Group

Empagliflozin lowers serum uric acid in chronic kidney disease: exploratory analyses from the EMPA-KIDNEY trial by Mayne, K, Sardell, R, Staplin, N, Judge, P, Zhu, D, Sammons, E, Emberson, J, Preiss, D, Landray, M, Baigent, C, Haynes, R, Herrington, W

Other Authors: “…EMPA-KIDNEY Collaborative Group…”

Design, recruitment, and baseline characteristics of the EMPA-KIDNEY trial by Herrington, W, Wanner, C, Green, JB

Other Authors: “…The EMPA-KIDNEY Collaborative Group…”

Frailty, multimorbidity and polypharmacy: exploratory analyses of the effects of empagliflozin from the EMPA-KIDNEY trial by Mayne, KM, Sardell, R, Staplin, N, Judge, P, Zhu, D, Sammons, E, Wanner, C, Emberson, J, Preiss, D, Landray, M, Baigent, C, Haynes, R, Herrington, W

Other Authors: “…EMPA-KIDNEY Collaborative Group…”

Empagliflozin in patients with chronic kidney disease by Herrington, WG, Staplin, N, Green, JB, Hauske, SJ, Emberson, J, Preiss, D, Judge, P, Mayne, K, Ng, S, Sammons, E, Zhu, D, Hill, M, Stevens, W, Wallendszus, K, Brenner, S, Cheung, AK, Liu, Z-H, Li, J, Hooi, LS, Wen Liu, Kadowaki, T, Nangaku, M, Levin, A, Cherney, D, Maggioni, AP, Pontremoli, R, Deo, R, Goto, S, Rossello, X, Tuttle, KR, Steubl, D, Petrini, M, Massey, D, Eilbracht, J, Brueckmann, M, Landray, M, Baigent, C, Haynes, R

Other Authors: “…EMPA-KIDNEY Collaborative Group…”